edaravone has been researched along with montelukast in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH | 1 |
| Fang, SH; Shi, WZ; Wei, EQ; Zhang, YM; Zhao, R | 1 |
2 other study(ies) available for edaravone and montelukast
| Article | Year |
|---|---|
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
Topics: Acetates; Animals; Antipyrine; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Chromones; Cyclopropanes; Dose-Response Relationship, Drug; Edaravone; Free Radical Scavengers; Infarction, Middle Cerebral Artery; Leukotriene Antagonists; Mice; Nervous System; Neuroprotective Agents; Psychomotor Performance; Quinolines; Receptors, Leukotriene; Sulfides; Survival Analysis; Time Factors | 2005 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
Topics: Acetates; Administration, Oral; Animals; Antipyrine; Atrophy; Behavior, Animal; Brain Injury, Chronic; Chromones; Cyclopropanes; Disease Models, Animal; Drug Evaluation, Preclinical; Edaravone; Free Radical Scavengers; Infarction, Middle Cerebral Artery; Injections, Intraperitoneal; Leukotriene Antagonists; Male; Mice; Mice, Inbred ICR; Nerve Degeneration; Quinolines; Rats; Rats, Sprague-Dawley; Sulfides | 2011 |